As a photosensitizing drug, the therapeutic agent for vulgaris vitiligo (Methoxsalen) plays a crucial role in the PUVA therapy (photochemotherapy) for vulgaris vitiligo. This drug exerts its therapeutic effect through a synergistic interaction with long-wave ultraviolet radiation (UVA), but it also carries a significant risk of phototoxicity.

Precautions for Administration of Therapeutic Agent for Vulgaris Vitiligo (Methoxsalen)

Confirmation of Indications

This therapeutic agent is indicated for patients with refractory vitiligo who do not respond to conventional treatments, and it should be used only after a clear pathological diagnosis is made.

The treatment must be administered and continuously supervised by physicians with professional qualifications in photochemotherapy.

Absolute Contraindications

A history of photosensitive diseases: Including lupus erythematosus, porphyria, xeroderma pigmentosum, etc.

Aphakia of the eye: The lack of lens protection significantly increases the risk of retinal damage.

A history of melanoma or invasive squamous cell carcinoma.

Idiosyncratic reactions: A history of allergy to psoralen compounds.

Basic Assessment Items

Skin type assessment: The initial UVA dose is determined based on the Fitzpatrick skin typing system.

Ophthalmic examination: Including slit-lamp examination to rule out early cataracts.

Hepatic and renal function tests: The drug is mainly metabolized by the liver, and renal function affects its excretion.

Pregnancy screening: Women of childbearing age must confirm their non-pregnant status.

Dosage Adjustments for Special Populations

Hepatic insufficiency: Dosage reduction is required, and enhanced monitoring should be implemented.

Elderly patients: Treatment should start from the lower end of the dosage range, with close attention to cardiovascular tolerance.

Pediatric patients: The safety of the drug has not been established, so a strict assessment of the risk-benefit ratio is necessary.

Key Precautions

Dosage form distinction: The bioavailability of soft capsules (Oxsoralen-Ultra) is twice that of hard capsules, and they are not interchangeable.

Dietary effects: It is recommended to take the drug with low-fat food or milk to reduce gastrointestinal reactions.

Management of missed doses: Skip the missed dose; do not make up for it or take a double dose.

Monitoring During Treatment with Therapeutic Agent for Vulgaris Vitiligo (Methoxsalen)

Monitoring of Phototoxic Reactions

Erythema assessment: A grading scale (Grade 0-4) is used; if erythema of Grade 2 or above occurs, treatment must be suspended.

Characteristics of incubation period: PUVA-induced erythema usually appears 24 hours after treatment and reaches its peak at 48-72 hours.

Management of burns: In case of severe burns, treatment must be terminated immediately and symptomatic treatment should be provided.

Ophthalmic Monitoring

Protection requirements: Patients must wear UVA-opaque goggles within 24 hours after treatment.

Regular examinations: Ophthalmic follow-up examinations should be conducted before treatment, in the first year after the start of treatment, and every two years thereafter.

Symptom warning: If symptoms such as blurred vision or halos appear, the patient must seek medical attention immediately.

Skin Tumor Screening

Baseline assessment: Record all suspicious skin lesions.

Regular examinations: Comprehensive skin examinations should be performed every 3-6 months, with a focus on non-melanoma skin cancers.

Self-examination: Educate patients to identify newly developed skin lesions and non-healing ulcers.

Laboratory Monitoring

Hepatic function: For patients undergoing long-term treatment, transaminase levels should be tested every 3-6 months.

Renal function: Creatinine clearance rate should be evaluated at least once a year for elderly patients.

Complete blood count: Pay attention to the changing trend of white blood cell counts.